Department of Respiratory Medicine, Gentofte University Hospital, Hellerup, Denmark.
Respiration. 2017;94(3):279-284. doi: 10.1159/000477625. Epub 2017 Jul 6.
Staging of lung cancer is essential to the treatment, which is curative only in cases of localized disease. Previous studies have suggested that endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is unnecessary when positron emission tomography-computed tomography (PET-CT) shows no mediastinal involvement.
The aim of the study was to investigate how often EBUS-TBNA resulted in a clinically relevant upstaging in patients with lung cancer without mediastinal involvement at PET-CT.
A total of 981 consecutive patients from 2009 to 2014 were referred for preoperative EBUS-TBNA. We included 167 patients with lung cancer without involvement of the mediastinum at PET-CT (115 N0 and 52 N1).
Of the 167 patients included, 10 (6.0%) were upstaged to N2 or N3 by EBUS-TBNA; 9 of these were originally classified as N1 at PET-CT. Therefore, 17.3% of the included N1 patients were upstaged to N2/N3 after EBUS-TBNA. This compares to only 0.9% of the N0 patients. After both EBUS-TBNA and PET-CT, 115 patients were operated, and 12 (10.4%) of these proved to be N2/N3. We calculated the sensitivity as 42.9%, the specificity as 99.0%, and the negative predictive value as 89.6%.
The overall probability of a clinically relevant upstaging by EBUS-TBNA in patients judged as N0/N1 at PET-CT was 6.0%, compared to 0.9% in patients classified as N0 and 17.3% in patients classified as N1. The risk of overlooking N2/N3 disease after both PET-CT and EBUS-TBNA was 10.4%.
肺癌分期对于治疗至关重要,只有局部疾病才能治愈。先前的研究表明,当正电子发射断层扫描-计算机断层扫描(PET-CT)显示无纵隔受累时,支气管内超声引导经支气管针吸活检(EBUS-TBNA)是不必要的。
本研究旨在探讨 PET-CT 显示无纵隔受累的肺癌患者中,EBUS-TBNA 导致临床相关分期升级的频率。
2009 年至 2014 年,共有 981 例连续患者被转介行术前 EBUS-TBNA。我们纳入了 167 例 PET-CT 显示无纵隔受累的肺癌患者(115 例 N0 和 52 例 N1)。
在纳入的 167 例患者中,10 例(6.0%)通过 EBUS-TBNA 分期升级为 N2 或 N3;其中 9 例最初在 PET-CT 中被归类为 N1。因此,EBUS-TBNA 后,纳入的 N1 患者中有 17.3%被升级为 N2/N3。相比之下,N0 患者中仅有 0.9%。在进行 EBUS-TBNA 和 PET-CT 后,有 115 例患者接受了手术,其中 12 例(10.4%)证实为 N2/N3。我们计算出的敏感性为 42.9%,特异性为 99.0%,阴性预测值为 89.6%。
在 PET-CT 评估为 N0/N1 的患者中,EBUS-TBNA 导致临床相关分期升级的总体概率为 6.0%,而在 N0 患者中为 0.9%,在 N1 患者中为 17.3%。在进行 PET-CT 和 EBUS-TBNA 后,漏诊 N2/N3 疾病的风险为 10.4%。